IGC Pharma
29 hedge funds and large institutions have $7.97M invested in IGC Pharma in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 6 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
57% more capital invested
Capital invested by funds: $5.08M → $7.97M (+$2.89M)
16% more funds holding
Funds holding: 25 → 29 (+4)
2.2% more ownership
Funds ownership: 7.62% → 9.81% (+2.2%)
11% less call options, than puts
Call options by funds: $805K | Put options by funds: $905K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$1.52M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$397K |
| 3 |
Vontobel Holding
Zurich,
Switzerland
|
+$218K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$121K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
-$227K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$52.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$45K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$44K |
| 5 |
VF
Virtu Financial
New York
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BMD
26
Better Money Decisions
Santa Fe,
New Mexico
| $1K | +$772 | +425 | New |
|
27
Barclays
London,
United Kingdom
| $1K | +$976 | +537 | New |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$45K | -28,742 | Closed |
|
|
SFI
29
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$44K | -28,200 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$33K | -21,135 | Closed |
|
31
Millennium Management
New York
| – | -$28K | -17,874 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | +$36 | +20 | +9% |
|
IGC Hedge Fund Activity: Q1 2021 in Review
29 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2021, worth a combined $7.97M — up 57% from $5.08M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IGC positions and 6 closed out — a net gain of 4 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was IQ EQ Fund Management, opening a new position worth an estimated $1.52M. The largest seller was Carroll Financial Associates, cutting an estimated $227K.
- 29 institutional investors held IGC Pharma (IGC) as of Q1 2021, up from 25 in Q4 2020.
- Funds reported $7.97M of IGC Pharma stock for Q1 2021, up 57% quarter-over-quarter.
- 10 funds opened new IGC Pharma positions in Q1 2021 and 6 closed out, a net change of +4 holders.
- The largest IGC Pharma buyer in Q1 2021 was IQ EQ Fund Management, an estimated $1.52M added.
- The largest IGC Pharma seller in Q1 2021 was Carroll Financial Associates, an estimated $227K sold.
Based on aggregated 13F filings for Q1 2021.